The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study (LAIV/EHPC)
Pneumonia, Influenza, Human
About this trial
This is an interventional health services research trial for Pneumonia focused on measuring Human challenge models, Immunity, Streptococcus pneumoniae, Live Attenuated Influenza Vaccine
Eligibility Criteria
Inclusion Criteria:
- have capacity to give informed consent
- aged 18-50 yrs - ages chosen to minimise the risk of pneumococcal infection
- speak fluent English- to ensure a comprehensive understanding of the research project and their proposed involvement, in order to minimise any communication issues to maximise participant safety.
Exclusion Criteria:
- currently involved in another study unless observational or in follow-up phase (non-interventional)
- received any influenza vaccine in the last 2 years
Sites / Locations
- Royal Liverpool Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
Study One: LAIV + Inoculation
Study One: Placebo + inoculation
Study Two: Inoculation + LAIV
Study Two: Inoculation + placebo
LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo